drugset / Trial / NCT03581071

Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients With Chronic Kidney Disease

NCT03581071 ↗

Phase 1 Completed 29 enrolled Taisho Pharmaceutical Co., Ltd.
Non-randomizedSequentialOpen-labelBasic science

Summary

To evaluate the safety, pharmacokinetics, and pharmacodynamics in nondialysis (ND) and hemodialysis (HD) subjects with Chronic Kidney Disease (CKD) who receive a single administration of TS-143.

Timeline

Start
2016-10-06
Primary completion
2017-07-06
Completion
2017-07-06

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-143 Unknown 1 mg Oral
Subject TS-143 Unknown 6 mg Oral
Subject TS-143 Unknown 11 mg Oral